South Africa’s Aspen Pharmacare says that its recent strategic moves to divest its Japanese business to Sandoz and sell its local Phekolong Pharmaceuticals South African subsidiary to Laurus Labs are helping it to better position itself in the face of “challenging” market conditions.
Aspen Makes Multiple Moves Amid Challenging Conditions
Deals With Laurus And Sandoz Position Firm For Future Growth
South Africa’s Aspen has made multiple strategic moves, including divesting its Japanese business to Sandoz and selling its local Phekolong Pharmaceuticals South African subsidiary to Laurus Labs, as part of efforts to better position itself in the face of “challenging” market conditions.

More from Strategy
As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.
More from Business
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.